WO2005080419A1 - Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations - Google Patents

Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations Download PDF

Info

Publication number
WO2005080419A1
WO2005080419A1 PCT/CN2003/000457 CN0300457W WO2005080419A1 WO 2005080419 A1 WO2005080419 A1 WO 2005080419A1 CN 0300457 W CN0300457 W CN 0300457W WO 2005080419 A1 WO2005080419 A1 WO 2005080419A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
protein
sars coronavirus
polypeptides
polypeptide
Prior art date
Application number
PCT/CN2003/000457
Other languages
English (en)
Chinese (zh)
Inventor
George F. Gao
Bo Tian
Jieqing Zhu
Gengfu Xiao
Congyi Zheng
Original Assignee
Institute Of Microbiology, Chinese Academy Of Sciences
Wuhan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Microbiology, Chinese Academy Of Sciences, Wuhan University filed Critical Institute Of Microbiology, Chinese Academy Of Sciences
Priority to AU2003246143A priority Critical patent/AU2003246143A1/en
Publication of WO2005080419A1 publication Critical patent/WO2005080419A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • Polypeptide medicament for inhibiting SARS coronavirus for inhibiting SARS coronavirus, its derivative and application thereof
  • the invention belongs to the field of molecular biology of viruses. Specifically, it involves the prevention and treatment of SARS coronavirus infection by using the heptad repeat (HR) HR1 and HR2 polypeptides and their derivatives of SARS coronavirus spike (S) protein. '
  • coronavirus corona The virus is an enveloped RNA virus. Similar to other enveloped viruses, it needs to release genetic material into cells through the fusion of viral envelopes and cell membranes to complete infection of cells. Fusion to most enveloped viruses Mechanism studies have found that they all use the envelope fusion glycoprotein to mediate the fusion of the virus envelope and the host cell membrane through conformational changes. These envelope glycoproteins (such as HA of influenza virus, gpl20 / g p41 of HIV, Ebola virus Gp and F protein of respiratory syncytial virus) have similar structural characteristics.
  • Heptad Repeat the research team has done related work in a variety of viruses, such as the human respiratory syncytial virus (Wang, E., Sun, X., Qian, Y., Zhao, L., Tien, P. and Gao, GF, BBRC. 2003, 302: 469-475.), Measles virus (Zhu, J., Zhang, C. W-H., Qi, Y., Tien, P. and Gao, GF, BBRC. 2002, 299: 897-902 .; Zhu,. J., Ding, Y., Gao,
  • viruses such as the human respiratory syncytial virus (Wang, E., Sun, X., Qian, Y., Zhao, L., Tien, P. and Gao, GF, BBRC. 2003, 302: 469-475.), Measles virus (Zhu, J., Zhang, C. W-H., Qi, Y.,
  • Menangle virus Za, J., Zhang, C. W-H., Rao, Z. Tien, P. and Gao
  • the envelope glycoprotein involved in the fusion of the coronavirus is spike (S) protein.
  • S spike
  • the present invention systematically analyzes the protein encoded by it and finds that there are also two characteristics on the Spike protein.
  • Heptad Repeat (HR1 and HR2), its position in the S protein please refer to Figure 1, the figure also compares the position of the HIV region in the envelope protein (GP160), which implies the SARS crown
  • GP160 HIV region in the envelope protein
  • the virus may have a similar fusion mechanism with HIV and the like.
  • the purpose of the present invention is to provide a method for blocking SARS coronavirus-infected cells using HR1 and HR2 polypeptides and derivatives thereof, wherein the amino acid sequence of the polypeptide is derived from two heptapeptides of SARS coronavirus spike (S) protein. Repeat regions (lieptad repeat, HR) HR1 and HR2.
  • the present invention provides the protein positions and amino acid sequences of the HR1 and HR2 regions of the SARS coronavirus spike protein, wherein HR1 has the amino acid sequence shown in Seq ID: No. 1; HR2 has the amino acid sequence shown in Seq ID: No.
  • Another object of the present invention is to provide a design of HR1 and HR2 polypeptides.
  • Method of functional analog The present invention also provides a method for preparing SARS coronavirus S protein HR polypeptide or its derivative by fusion expression.
  • the HR polypeptide and its derivatives obtained through expression purification or artificial synthesis have inhibitory activity on SARS virus-infected cells, and can be developed into peptide drugs for preventing and treating SARS diseases.
  • the present invention provides the following two methods to obtain HR polypeptide or its derivative:
  • polypeptides corresponding to HR1 and HR2 were artificially synthesized and identified by HPLC with a purity of greater than 90%.
  • the HR1 and HR2 genes were artificially spliced and cloned into the GST fusion expression vector pGEX-6p-1 using the BamH I / 3 ⁇ 4ho I restriction site. The DNA sequence was determined to be correct for the obtained gene sequence.
  • PGEX- 6p- 1 / HR1 and pGEX- 6p- 1 / HR2 were transformed into E.coli BL21 (DE3) competent cells, respectively. Monoclonal inoculation with an appropriate amount of ampicillin (100 g / ml) containing 2 X YTA liquid medium was selected.
  • ultrasonic lysing bacteria # after ultrasonic lysis, add TritonX-100 at a final concentration of 1%, ice bath for 30 min, centrifuge at 12000 rpm, 4 ° C for 15 min, and take the supernatant; pass the ultrasonic lysed supernatant through GlutathLione- Sepharose 4B affinity chromatography column, then wash the affinity column with PBS for at least ten column volumes; wash with at least three column volumes of reduced glutathione solution (lOrnM reduced glutathione, 50mM Tris-HCl pH 8.
  • the HR1 or HR2 protein was obtained from the solution, and then concentrated to an appropriate concentration using an ultrafiltration tube with a cutoff molecular weight of 3K, and further purified by reversed-phase HPLC. Protein samples were identified by 12% SDS-PAGE or Tris-tricine SDS-PAGE. Egg S concentration was determined using BCA protein detection kit (Pierce).
  • the human GST protein gene was fused with the SARS coronavirus spike eggs HR1 and HR2 or their derivatives, and the fusion protein was directly used to inhibit SARS coronavirus infection of the meninges.
  • the present invention provides a method for designing the functional classes-analogues of SARS coronavirus spike eggs S HR1 and HR2 polypeptides. Due to the strong hydrophobicity of HR1 peptide, it is easy to accumulate, and its stability is not good, which affects its function.
  • the present invention uses amino acid linkers to connect HR1, HR2, and HR1 in tandem (referred to as HR121) for expression and purification, and simultaneously connect five polypeptides of HR1, HR2, HR1, HR2, and HR1 (referred to as 5-Helix) for expression and purification. After purification, the stability of HR121 and 5-Helix is higher than that of HR1 polypeptide alone, and its function is the same.
  • the three HR2 and HRK HR2 polypeptides are connected in series (referred to as HR212) for expression and purification.
  • HR212 the obtained HR212 protein is also more stable and easier to purify than the individual HR2 polypeptide, and its function is similar to that.
  • the present invention provides a method for blocking SARS virus-infected cells using SARS coronavirus spike protein HR1 and HR2 polypeptides or derivatives thereof.
  • the HR polypeptide obtained by the above artificial synthesis or genetic engineering method or the HR protein fused with GST or other proteins is diluted with a fixed concentration of SARS coronavirus, and then co-adsorbed with Vero and other cultured cells. Effects on SARS coronavirus-producing cytopathy (CPE).
  • CPE SARS coronavirus-producing cytopathy
  • the results show that HR polypeptide or GST-HR can inhibit the production of CPE in the concentration range of nM, indicating that HR polypeptide can block the infection of SARS coronavirus to cells.
  • HR polypeptides or real derivatives can be used to develop drugs to prevent SARS virus infection.
  • FIG 1 Schematic diagram of the SARS coronavirus spike (S) protein. The possible S1 and S2 subunits and the transmembrane domain and cytoplamic domain are shown. A computer program predicts that HR1 and HR2 are in the Boxing position of the S protein and are simultaneously associated with HIV-1 The comparison of HR1 and HR2 prediction results of gpl60 shows that they have similar structural characteristics.
  • Figure 2 Schematic diagram of constructing functional analogs of HR1 and HR2 peptides.
  • 5-Helix is HRllinkerlHR21inker2HRllinkerlHR21inker2HRl
  • HR121 is HRllinkerlHR21inker2HRl
  • HR212 is HR21inker2HRllinke rlHR2, where the amino acid sequence of linkerl is SGGRGG (letter represents the abbreviation of amino acid in English), and the amino acid sequence of linker2 is GGSGG (letter).
  • 5- He lix and HR121 function similarly to the HR1 polypeptide
  • HR212 functions similarly to the HR2 polypeptide.
  • the SARS coronavirus S protein sequence was from a Toronto isolate, and the gene accession number was: NC—004718.
  • the computer program was used to analyze the S protein, which showed that the SARS coronavirus S protein has two typical heptad repeat sequences. At the same time, other different programs were used to analyze the results. The positions of HR1 and HR2 were similar. Finally, the HR1 sequence was identified as Seq ID: No. 1; HR2 sequence is Seq ID: No. 2.
  • the HR2 polypeptide was artificially synthesized; three HR1 polypeptides of different lengths were synthesized at the same time, and the purity was identified by HPLC to be more than 90%, and the synthesized peptide was very soluble.
  • the HR1 gene was spliced as follows: In the first step, S (hrl) 1- S (hrl) 10 ten primers (0.20 ⁇ / ⁇ 1) were mixed and amplified according to the following PCR conditions: denaturation at 94 ° C for 5 min, and then 94 ° C 1.5 min, 55 ° C 2 min, 72 ° C 1 min, 25 cycles; in the second step, S (hrl) l and S (hrl) 10 were used as primers, and the first PCR product was used as a template. Conditions for PCR amplification. The PCR product was recovered by absolute ethanol precipitation and identified by 1% agarose electrophoresis.
  • Each of the two adjacent primers has an 18-base complementary sequence, and is designed with BamHI and Xho I restriction sites and a stop codon. Primers are synthesized synthetically.
  • the HR2 gene was spliced as follows: In the first step, S (hr2) l- S (hr2) 4 four primers (0.20 ⁇ / ⁇ 1) were mixed, and the amplification was performed according to ⁇ J PCR conditions: denaturation at 94 ° C for 5 minutes, and then 94.
  • the PCR product was used as a template, and PCR amplification was performed under the same conditions.
  • the PCR product was recovered by anhydrous ethanol precipitation and identified by 1% agarose electrophoresis.
  • the obtained gene was double-digested with BamH 1 and Xho I, ligated to the same double-digested pGEX-6p-1 vector, and positive clones were selected by the method of enzyme digestion identification. Finally, DNA sequence analysis proved that the obtained HR2 gene was completely correct.
  • DNA sequencing pGEX_6p_l / HRl and pGEX_6p-1 / HR2 were used to transform E. coli BL21 (DE3) competent cells, respectively. Monoclonal inoculation with ampicillin (100 pg / ml) containing 2 X YTA liquid medium (tryptone) was selected. 16g, yeast extract 10g, sodium chloride 5g, water 10Q0ml), shake culture at 37 ° C overnight as seed liquid; seed solution is inoculated with fresh 2 XYTA liquid medium at 1/100 inoculation amount, shake culture at 37 ° C To 0D 59 .
  • ampicillin 100 pg / ml
  • 2 X YTA liquid medium tryptone
  • the permeate was collected to obtain HR1 or HR2
  • the protein was concentrated to an appropriate concentration in an ultrafiltration tube with a cut-off molecular weight of 3K, and further purified by reversed-phase HPLC, and 7CTC was frozen for future use.
  • the protein samples were identified by 12% Tris-tricine SDS-PAGE. The results showed that the HRr polypeptide was about 12 kDa and the HR2 polypeptide was about 4 kDa, which was consistent with the expected size.
  • the protein concentration was determined using a BCA protein detection kit (Pierce). 6. Fusion table of SARS coronavirus HR1 and HR2 polypeptides with human GST
  • the human GST and HR1 or HR2 polypeptides were fusion-expressed and purified according to the same method as in Example 5, and the obtained GST-HR protein was directly used to test its activity for inhibiting SARS coronavirus-infected cells.
  • the GST-HR1 purified according to the method of Example 5 was mixed with the expressed and purified HR2 or artificially synthesized HR2 polypeptide, and the mixture was reacted for 1 hour at room temperature, and then mixed with an appropriate amount of Glutathione-Sepharose 4B affinity filler. After 30 minutes at room temperature, PBS buffer Washed three times, then eluted with reduced glutathione solution, and finally identified by 12% Tris-tricine SDS-PAGE. The results show that GST-HR1 can specifically bind to HR2 polypeptide expressed or purified synthetically, indicating that HR1 or The HR2 polypeptide and its derivatives exert inhibitory activity by binding to the corresponding HR region on the S protein of the virus. 8. Inhibition of SARS virus-infected cultured cells by the HR polypeptide or its derivative obtained by the methods of Examples 2, 5, and 6
  • Vero E6 cells were cultured in DMEM medium (containing 100 U / ml cyanoconductor, 10% fetal bovine serum) at 37 ° C; 5% ⁇ 2 incubator to grow into a monolayer.
  • the HR polypeptide and its derivatives obtained in the methods of Examples 2, 5, and 6 were sterilized by filtration, and diluted by a multiple (the initial concentration was 100 ⁇ M) with a fixed concentration of SARS coronavirus.
  • the virus TCID 50 is 5
  • the cells were adsorbed together. After 1 hour at 37 ° C, the virus and peptide mixture was aspirated and DMEM maintenance solution (containing 100U / ml penicillin, 2% fetal bovine serum) was added.
  • CPE cytopathic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un procédé d'utilisation d'un polypeptide et de son dérivé afin d'éviter l'infection par coronavirus SARS dans une cellule, la séquence d'acides aminés du polypeptide dérivé de deux régions à répétition heptade (HR), HR1 et HR2 de la protéine spicule (S) du coronavirus SARS: Un procédé de production d'un polypeptide HR de la protéine S du coronavirus ou ses dérivés par expression par fusion. Le polypeptide HR et ses dérivés obtenus par expression et purification ou synthèse artificielle, sont tous aptes à inhiber l'infection SARS dans une cellule, d'où leur utilisation pour la préparation d'agents polypeptides en vue de la prévention et du traitement de la maladie SARS.
PCT/CN2003/000457 2003-05-16 2003-06-12 Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations WO2005080419A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003246143A AU2003246143A1 (en) 2003-05-16 2003-06-12 Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN03136220.6 2003-05-16
CNB031362206A CN1223605C (zh) 2003-05-16 2003-05-16 抑制sars冠状病毒的多肽药物及其衍生物和其应用

Publications (1)

Publication Number Publication Date
WO2005080419A1 true WO2005080419A1 (fr) 2005-09-01

Family

ID=34154758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000457 WO2005080419A1 (fr) 2003-05-16 2003-06-12 Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations

Country Status (3)

Country Link
CN (1) CN1223605C (fr)
AU (1) AU2003246143A1 (fr)
WO (1) WO2005080419A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647048A (zh) * 2020-06-22 2020-09-11 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
CN100339396C (zh) * 2005-04-18 2007-09-26 中国科学院微生物研究所 抑制i型人免疫缺陷病毒感染的三螺旋蛋白及其编码基因与应用
US8470771B2 (en) 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
CN101186637B (zh) * 2007-11-14 2011-09-14 中国科学院微生物研究所 抑制流感病毒感染的方法及其药物
CN107245095B (zh) * 2017-06-15 2020-05-26 武汉大学 用于抑制十种冠状病毒的多肽抑制剂
CN113264990B (zh) * 2020-02-14 2022-09-27 深圳大学 抑制新型冠状病毒(sars-cov-2)的多肽和其应用
CN111349150B (zh) * 2020-03-24 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制新型冠状病毒的多肽及其用途
CN111518163B (zh) * 2020-04-08 2022-04-12 大连百奥泰科技有限公司 一类脂肽化合物在抗新型冠状病毒中的应用
US20220323537A1 (en) * 2020-06-22 2022-10-13 Kunming Institute Of Zoology, Chinese Acadamy Of Sciences USE OF INTERFERENCE PEPTIDE IN PREPARATION OF ANTI-SARS-CoV-2 MEDICAMENT
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
CA3231587A1 (fr) * 2021-09-08 2023-03-16 Dana-Farber Cancer Institute, Inc. Conjugues peptide-cholesterol de sars-cov-2 antiviraux structurellement inseres et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007987A2 (fr) * 1993-09-16 1995-03-23 Solvay S.A. Nouveaux polypeptides/proteines, plasmides de cotransfection et leurs vecteurs recombinants vivants
WO1998049195A1 (fr) * 1997-04-29 1998-11-05 Universiteit Utrecht Particules de type coronavirus utilisees comme outils pour la vaccination et le traitement
WO2001064013A2 (fr) * 2000-02-29 2001-09-07 Trimeris, Inc. Procedes et compositions utiles pour inhiber les evenements associes a la fusion de membrane y compris la transmission du virus respiratoire syncytial
WO2001074295A2 (fr) * 2000-03-31 2001-10-11 The Scripps Research Institute Phospholipid scramblases et leurs methodes d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007987A2 (fr) * 1993-09-16 1995-03-23 Solvay S.A. Nouveaux polypeptides/proteines, plasmides de cotransfection et leurs vecteurs recombinants vivants
WO1998049195A1 (fr) * 1997-04-29 1998-11-05 Universiteit Utrecht Particules de type coronavirus utilisees comme outils pour la vaccination et le traitement
WO2001064013A2 (fr) * 2000-02-29 2001-09-07 Trimeris, Inc. Procedes et compositions utiles pour inhiber les evenements associes a la fusion de membrane y compris la transmission du virus respiratoire syncytial
WO2001074295A2 (fr) * 2000-03-31 2001-10-11 The Scripps Research Institute Phospholipid scramblases et leurs methodes d'utilisation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647048A (zh) * 2020-06-22 2020-09-11 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides

Also Published As

Publication number Publication date
CN1223605C (zh) 2005-10-19
AU2003246143A1 (en) 2005-09-05
CN1488641A (zh) 2004-04-14

Similar Documents

Publication Publication Date Title
US20220202934A1 (en) Respiratory virus nucleic acid vaccines
CN111560074B (zh) 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
ES2589057T3 (es) Proteína quimérica
JP2024513999A (ja) インフルエンザ－コロナウイルス組み合わせワクチン
JP2024514182A (ja) 呼吸器ウイルス組み合わせワクチン
WO2005080419A1 (fr) Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations
WO2009062348A1 (fr) Procédés d'inhibition d'une infection par le virus de la grippe et leurs médicaments
Basak et al. Reviewing Chandipura: a vesiculovirus in human epidemics
CN112552413B (zh) 新型冠状病毒重组蛋白亚单位疫苗
CN113425832A (zh) 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
EP0366238A2 (fr) Polypeptides vaccinaux d'influenza
Ni et al. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain
WO2006025536A1 (fr) Agent anti-virus du sras
Wang et al. Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins
KR102332725B1 (ko) 오량체 기반 재조합 단백질 백신 플랫폼 및 이를 발현하는 시스템
US20210040153A1 (en) Oligopeptide having dengue virus replication inhibition function and application thereof
WO2023069498A1 (fr) Composition de vaccin à base d'arnm
WO2021235503A1 (fr) Monomère protéique conjugué supportant la protéine du coronavirus, agrégat desdits monomères, et composant vaccinal comprenant ledit agrégat comme principe actif
WO2021039873A1 (fr) Monomère de protéine composite ayant une protéine non structurale de virus supportée sur celui-ci, agrégat de monomère de protéine composite, et vaccin à composants comprenant un agrégat en tant que principe actif
AU640348B2 (en) Vaccinal Polypeptides
Zhu et al. Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion
CN112587522B (zh) 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用
US20240226277A1 (en) Influenza-coronavirus combination vaccines
CN116763902B (zh) 抗冠状病毒脂肽在治疗和预防流行性感冒中的用途
US20240216500A1 (en) Respiratory virus combination vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP